A recent study suggests that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end conventional lifestyle regimens.
Research printed in a prominent medical journal points out that while overweight individuals can lose a large proportion of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month upon discontinuation.
"Users buying these drugs must be informed of the potential of rapid weight regain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to original mass in about one and a half years.
Analyzing Approaches
The research, which looked at 37 of studies involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with other pills.
The team emphasize that individuals who lose weight through dieting typically have a slower creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Doctors believe the mode of action of the jabs accounts for the amplified weight return.
These medications imitate a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than normal might result in the system to produce less of its endogenous hormone, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement leads to hunger is unsuppressed, making overeating much more probable."
A Lifelong Issue?
Health authorities advise the jabs for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
Many experts say that, given the likelihood of weight regain, the treatment is often ongoing.
This perspective is echoed by pharmaceutical companies, who say that the results "emphasize the chronic character of obesity," akin to managing diseases like diabetes.
User Testimonies
Users who have discontinued the medication describe a intense resurgence of cravings.
"I experienced a trigger activating and I was suddenly ravenous," described one woman.
This difficulty is worsened if users have not adopted lasting lifestyle or habit changes during therapy.
Growing Interest
Recent estimates suggest that millions of adults in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is more common among females than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while the jabs are potent tools for shedding pounds, they are not a standalone solution and maintained weight loss likely depends on integrated lifestyle changes.
